Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A thieno[2,3-c]pyridine compound of the formula 2-[[4-[[ethyl(phenylmethyl)amino]sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide.

2. (Original) A thieno[2,3-c]pyridine compound of the formula 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide.

3. (Currently Amended) A pharmaceutical composition comprising as an active ingredient a compound of the general formula I:



wherein:

R_1 is selected from the group consisting of H; straight or branched alkyl of 1-6 carbon atoms; arylalkyl; substituted arylalkyl; cycloalkyl, optionally substituted with alkyl groups; alkanoyl; arylcarbonyl optionally substituted at the aryl group; cycloalkylcarbonyl; alkoxycarbonyl;

R_2 is selected from the group consisting of ~~carboxy; cyano~~;

aminocarbonyl; alkylaminocarbonyl; arylaminocarbonyl optionally substituted at the aryl group; dialkylaminocarbonyl wherein each alkyl is straight or branched chain C_1-C_6 alkyl or both alkyl groups together may form a 3-7 membered saturated, unsaturated or aromatic monocyclic or bicyclic nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms; ~~alkoxycarbonyl; alkanoyl; cycloalkylcarbonyl; arylcarbonyl optionally substituted on the aryl group,~~ benzothiazol-2-yl;

R_3 and R_4 are selected from the group consisting of C_1-C_6 alkyl, optionally substituted by hydroxy, alkoxy, amino or alkylamino, C_2-C_4 monounsaturated alkenyl, cycloalkyl, aryl, arylmethyl, or R_3 and R_4 together may form an optionally substituted 5-7 membered saturated, monocyclic ~~or bicyclic~~ nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms, or R_3 and R_4 together may form an optionally substituted 5-7 membered unsaturated or aromatic monocyclic or bicyclic nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms;

R_5, R_6, R_7 and R_8 are selected from the group consisting of H or C_1-C_6 alkyl, with the proviso that when R_5, R_6, R_7 and R_8 are C_1-C_6 alkyl, R_1 is hydrogen;

and pharmaceutically acceptable salts thereof; further comprising a pharmaceutically acceptable diluent or carrier.

4. (Original) The pharmaceutical composition according to claim 3, wherein R_1 is selected from the group consisting of methyl, ethyl, 1-methylethyl, phenylmethyl, acetyl, ethoxycarbonyl and R_5 =R_6 =R_7 =R_8 are hydrogens.

5. (Original) The pharmaceutical composition according to claim 3, wherein R_1 is hydrogen and R_5 =R_6 =R_7 =R_8 are

hydrogens or methyl groups.

6. (Original) The pharmaceutical composition according to claim 3, wherein R_1 =R_5 =R_6 is methyl and R_7 =R_8 are hydrogens.

7. (Currently Amended) The pharmaceutical composition according to claim 3, wherein R_2 is selected from the group consisting of ~~cyano, methoxycarbonyl, ethoxycarbonyl,~~ aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, benzothiazol-2-yl.

8. (Original) The pharmaceutical composition according to claim 3, wherein R_3 and R_4 are selected from the group consisting of methyl, ethyl, propyl, butyl, methoxyethyl, chlorobutyl, cyanoethyl, phenyl, cyclopentyl, cyclohexyl, phenylmethyl, allyl or crotyl, R_3 and R_4 may be equal or different.

9. (Currently Amended) The pharmaceutical composition according to claim 3, wherein R_3 and R_4 form pyrrolidine, piperidine, 2-methyl, 3-methyl, 4-methyl or 3,5-dimethyl piperidine, perhydroazepine, morpholine, piperazine, 4-methylpiperazine, 3,4-dihydro-2(1H)-isoquinolinyl, 3,4-dihydro-1(2H)quinoline, ~~1,3,3-trimethyl-6-azabicyclo[3.2.1] oct-6-ane~~ and substituted derivatives thereof.

10. (Currently Amended) The pharmaceutical composition according to claim 3 wherein the compound of Formula I is selected from:

2-[[4-[(ethylbutylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-

c]pyridine;

2-[[(4-(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl] benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[4-(methylphenylamino)sulfonyl] benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[4-(3,4-dihydro- 2(1H)-isoquinolinyl)sulfonyl] benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl thieno[2,3-c]pyridine-3-carboxamide;2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-(morpholinylsulfonyl) benzoyl]amino]-3-(benzothiazol-2-yl)-6-(1-methylethyl)-4,5,6,7-etrahydrothieno [2,3-c]pyridine;

~~2-[[4-(diethylamino)sulfonyl]-benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

2-[[4-(3,4-dihydro-1(2H)-quinolinyl)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine;

~~2-[[4-(hexahydro-1H-azepin-1-yl)sulfonyl]-benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

2-[[4-[[4-(methyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

~~2-[[4-[(1,3,3-trimethyl-6-azabicyclo-[3.2.1]oct-6-yl)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;~~

2-[[4-[(methylphenylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-

c]pyridine;

2-[[4-(morpholinylsulfonyl) benzoyl] amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

~~2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-6-carboxylic acid ethyl ester;~~

2-[[4-[[4-(3-methyl-1-piperidinyl)]sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-(phenylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

2-[[4-[(cyclohxylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

~~2-[[4-[(di-2-propenylamino)sulfonyl]benzoyl]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxylic acid methyl ester;~~

2-[[4-[(di-2-methoxyethylamino)]sulfonyl]benzoyl]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

~~2-[[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1.]oct-6-yl)sulfonyl]benzoyl]amino]-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;~~

2-[[4-[(diethylamino) sulfonyl]benzoyl]amino]-3-

(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(di-2-methoxyethylamino)sulfonyl]benzoyl]-amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydro thieno[2,3-c]pyridine;

2-[[4-[(methylphenylamino)sulfonyl]benzoyl] amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydro- thieno[2,3-c]pyridine;

2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7- tetrahydrothieno[2,3-c]pyridine;

~~2-[[4-[(methylbutylamino)sulfonyl]benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

~~2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

2-[[4-(diethylamino)sulfonyl] benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

2-[[4-[(methylphenylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[[ethyl(phenylmethyl)amino]sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c] pyridine-3-carboxamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[(4-(3,4-dihydro-1(2H)-quinolinyl)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl] benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl] benzoyl] amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4- (diethylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid N-methylamide;

2-[[4- (diethylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid morpholinylamide.

11. (Currently Amended) The pharmaceutical composition according to claim 10 wherein the compound of formula I is: 2-[[4-[(ethylbutylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine~~,~~.

12. (Currently Amended) The pharmaceutical composition according to claim 10 wherein the compound of formula I is: 2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine~~,~~.

13. (Original) The pharmaceutical composition according to claim 10 wherein the compound of formula I is:

2-[[4-[[ethyl(phenylmethyl)amino] sulfonyl]benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydro thieno[2,3-c]pyridine-3-carboxamide.

14. (Original) The pharmaceutical composition according to claim 10 wherein the compound of formula I is:

2-[[4-[(4-ethyl-1-piperazinyl)sulfonyl] benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3-carboxamide.

Claims 15-20 (Cancelled).

21. (Currently Amended) A method for the treatment or prevention of diseases or disorders related to cell adhesion or cell migration mediated by GAG-~~ECAM~~ L-selectin interactions, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the general formula I:



wherein:

R_1 is selected from the group consisting of H; straight or branched alkyl of 1-6 carbon atoms; arylalkyl; substituted arylalkyl; cycloalkyl, optionally substituted with alkyl groups; alkanoyl; arylcarbonyl optionally substituted at the aryl group; cycloalkylcarbonyl; alkoxycarbonyl;

R_2 is selected from the group consisting of ~~carboxy; cyano~~; aminocarbonyl; alkylaminocarbonyl; arylaminocarbonyl optionally substituted at the aryl group; dialkylaminocarbonyl

wherein each alkyl is straight or branched chain C_1-C_6 alkyl or both alkyl groups together may form a 3-7 membered saturated, unsaturated or aromatic monocyclic or bicyclic nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms; ~~alkoxycarbonyl; alkanoyl; cycloalkylcarbonyl; arylcarbonyl optionally substituted on the aryl group,~~ benzothiazol-2-yl;

R_3 and R_4 are selected from the group consisting of C_1-C_6 alkyl, optionally substituted by hydroxy, alkoxy, amino or alkylamino, C_2-C_4 monounsaturated alkenyl, cycloalkyl, aryl, arylmethyl, or R_3 and R_4 together may form an optionally substituted 5-7 membered saturated, monocyclic ~~or bicyclic~~ nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms, or R_3 and R_4 together may form an optionally substituted 5-7 membered unsaturated or aromatic monocyclic or bicyclic nitrogen containing heterocyclyl, optionally containing one or two additional heteroatoms;

R_5, R_6, R_7 and R_8 are selected from the group consisting of H or C_1-C_6 alkyl, with the proviso that when R_5, R_6, R_7 and R_8 are C_1-C_6 alkyl, R_1 is hydrogen;

and pharmaceutically acceptable salts thereof; further comprising a pharmaceutically acceptable diluent or carrier.

22. (Original) The method according to claim 21 wherein R_1 is selected from the group consisting of methyl, ethyl, 1-methylethyl, phenylmethyl, acetyl, ethoxycarbonyl and R_5 =R_6 =R_7 =R_8 are hydrogens.

23. (Original) The method according to claim 21 wherein R_1 is hydrogen and R_5 =R_6 =R_7 =R_8 are hydrogens or methyl groups.

24. (Original) The method according to claim 21 wherein R_1 =R_5 =R_6 is methyl and R_7 =R_8 are hydrogens.

25. (Currently Amended) The method according to claim 21 wherein R_2 is selected from the group consisting of ~~cyano, methoxycarbonyl, ethoxycarbonyl~~aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, (3,5-dimethyl-1H-pyrazolyl) carbonyl, benzothiazol-2-yl.

26. (Original) The method according to claim 21 wherein R_3 and R_4 are selected from the group consisting of methyl, ethyl, propyl, butyl, methoxyethyl, chlorobutyl, cyanoethyl, phenyl, cyclopentyl, cyclohexyl, phenylmethyl, allyl or crotyl, R_3 and R_4 may be equal or different.

27. (Currently Amended) The method according to claim 21 wherein R_3 and R_4 form pyrrolidine, piperidine, 2-methyl, 3-methyl, 4-methyl or 3,5-dimethyl piperidine, perhydroazepine, morpholine, piperazine, 4-methylpiperazine, 3,4- dihydro-2(1H)-isoquinolinyl, 3,4-dihydro-1(2H)quinoline, ~~1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-ane~~ and substituted derivatives thereof.

28. (Currently Amended) The method according to claim 21 wherein the compound of formula I is selected from:

2-[[4-[(ethylbutylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[(4-(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl] benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[4-(methylphenylamino)sulfonyl] benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[4-(3,4-dihydro- 2(1H)-isoquinolinyl)sulfonyl] benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl thieno[2,3-c]pyridine-3-carboxamide;

2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-(morpholinylsulfonyl) benzoyl]amino]-3-(benzothiazol-2-yl)-6-(1-methylethyl)-4,5,6,7-etrahydrothieno [2,3-c]pyridine;

~~2-[[4-(diethylamino)sulfonyl] benzoyl]amino] 4,5,6,7-tetrahydro 5,5,7,7 tetramethyl thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

2-[[4-(3,4-dihydro-1(2H)-quinolinyl)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine;

~~2-[[4-(hexahydro-1H-azepin-1-yl)sulfonyl] benzoyl] amino] 4,5,6,7 tetrahydro 5,5,7,7 tetramethyl thieno[2,3-c]pyridine 3 carboxylic acid ethyl ester;~~

2-[[4-[[4-(methyl)-1-piperazinyl]sulfonyl]benzoyl] amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

~~2-[[4-[(1,3,3 trimethyl 6 azabicyclo [3.2.1]oct 6-yl)sulfonyl]benzoyl]amino] 3 (benzothiazol 2 yl) 6 methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;~~

2-[[4-[(methylphenylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-(morpholinylsulfonyl) benzoyl] amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-

c]pyridine;

~~2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-6-carboxylic acid ethyl ester;~~

2-[[4-[[4-(3-methyl-1-piperidinyl)]sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-(phenylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

2-[[4-[(cyclohxylmethylamino)sulfonyl]benzoyl] amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

~~2-[[4-[(di-2-propenylamino)sulfonyl]benzoyl]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxylic acid methyl ester;~~

2-[[4-[(di-2-methoxyethylamino)]sulfonyl]benzoyl]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

~~2-[[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1.]oct-6-yl)sulfonyl]benzoyl]amino]-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;~~

2-[[4-[(diethylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(diethylamino) sulfonyl]benzoyl]amino]-3-

(benzothiazol-2-yl)-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

2-[[4-[(di-2-methoxyethylamino)sulfonyl]benzoyl]-amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydro thieno[2,3-c]pyridine;

2-[[4-[(methylphenylamino)sulfonyl]benzoyl] amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydro- thieno[2,3-c]pyridine;

2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine;

~~2-[[4-[(methylbutylamino)sulfonyl]benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

~~2-[[4-[[4-(ethoxycarbonyl)-1-piperazinyl]sulfonyl] benzoyl]amino]-6-(1-methylethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid ethyl ester;~~

2-[[4-(diethylamino)sulfonyl] benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridine-3-carboxamide;

2-[[4-[(methylphenylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[[ethyl(phenylmethyl)amino]sulfonyl] benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c] pyridine-3-carboxamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7- tetrahydrothieno[2,3-c]pyridine-3-carboxamide;

2-[[(4-(3,4-dihydro-1(2H)-quinolinyl)sulfonyl] benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl] benzoyl] amino]

-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid methylamide;

2-[[4-[(4-methyl-1-piperazinyl)sulfonyl] benzoyl] amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno [2,3-c]pyridine;

2-[[4-(diethylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid N-methylamide;

2-[[4- (diethylamino)sulfonyl] benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid morpholinylamide.

29. (Currently Amended) The method according to claim 28 wherein the compound of formula I is:

2-[[4-[(ethylbutylamino) sulfonyl]benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine~~,~~.

30. (Currently Amended) The method according to claim 28 wherein the compound of formula I is:

2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine~~,~~.

31. (Original) The method according to claim 28 wherein the compound of formula I is:

2-[[4-[[ethyl(phenylmethyl)amino]sulfonyl]benzoyl] amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide.

32. (Original) The method according to claim 28 wherein the compound of formula I is:

2-[[4-[(4-ethyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-

ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide.

33. (Currently Amended) The method according to claim 21 wherein the disease or disorder related to cell adhesion or cell migration is ~~selected from the group consisting of~~ an inflammatory process~~, an autoimmune process or disease, platelet-mediated pathologies, tumor metastasis, viral diseases, atherosclerosis, amyloid disorders, and kidney disease~~.

Claims 34-41 (Cancelled).

42. (Original) A method for the prevention or treatment of inflammatory bowel disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a thieno[2,3-c]pyridine compound of formula 2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine and a pharmaceutically acceptable salt thereof; further comprising a pharmaceutically acceptable carrier or diluent.

43. (Original) A method for the prevention or treatment of multiple sclerosis comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a thieno[2,3-c]pyridine compound of formula 2-[[4-[(diethylamino)sulfonyl] benzoyl]amino]-3-(benzothiazol-2-yl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine and a pharmaceutically acceptable salt thereof; further comprising a pharmaceutically acceptable carrier or diluent.